Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 269

1.

Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulations.

Grau-Expósito J, Luque-Ballesteros L, Navarro J, Curran A, Burgos J, Ribera E, Torrella A, Planas B, Badía R, Martin-Castillo M, Fernández-Sojo J, Genescà M, Falcó V, Buzon MJ.

PLoS Pathog. 2019 Aug 19;15(8):e1007991. doi: 10.1371/journal.ppat.1007991. eCollection 2019 Aug.

2.

Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab.

Serra-Peinado C, Grau-Expósito J, Luque-Ballesteros L, Astorga-Gamaza A, Navarro J, Gallego-Rodriguez J, Martin M, Curran A, Burgos J, Ribera E, Raventós B, Willekens R, Torrella A, Planas B, Badía R, Garcia F, Castellví J, Genescà M, Falcó V, Buzon MJ.

Nat Commun. 2019 Aug 16;10(1):3705. doi: 10.1038/s41467-019-11556-4.

3.

Outcomes by sex following treatment initiation with darunavir/cobicistat in a large Spanish cohort of the CODAR study (GeSIDA 9316).

Pérez Elías MJ, Alejos B, Vivancos MJ, Ribera E, Galindo MJ, Vilanova-Trillo L, García-Fraile Fraile LJ, de La Fuente Moral S, Garcia De Lomas J, Lozano F, Mateo García MG, Tasias Pitarch M, Diez Martinez M, Rojas J, Raya-Cruz M, Sepúlveda MA, Troya J, Del Campo S, Martinez E.

J Antimicrob Chemother. 2019 Oct 1;74(10):3124. doi: 10.1093/jac/dkz331. No abstract available.

PMID:
31377772
4.

Outcomes by sex following treatment initiation with darunavir/cobicistat in a large Spanish cohort of the CODAR study (GeSIDA 9316).

Pérez Elías MJ, Alejos B, Vivancos MJ, Ribera E, Galindo MJ, Vilanova-Trillo L, García-Fraile Fraile LJ, de La Fuente Moral S, Garcia De Lomas J, Lozano F, Mateo García MG, Tasias Pitarch M, Diez Martinez M, Rojas J, Raya-Cruz M, Sepúlveda MA, Troya J, Del Campo S, Martinez E; CODAR study group .

J Antimicrob Chemother. 2019 Oct 1;74(10):3044-3048. doi: 10.1093/jac/dkz254.

PMID:
31236601
5.

Effectiveness of Once/Day Dolutegravir Plus Boosted Darunavir as a Switch Strategy in Heavily Treated Patients with Human Immunodeficiency Virus.

Navarro J, Santos JR, Silva A, Burgos J, Falcó V, Ribera E, Imaz A, Curran A.

Pharmacotherapy. 2019 Apr;39(4):501-507. doi: 10.1002/phar.2227. Epub 2019 Mar 22.

PMID:
30723941
6.

New Dual Combination of Dolutegravir-Rilpivirine for Switching to Maintenance Antiretroviral Therapy.

Ribera E.

AIDS Rev. 2018;20(4):179-186. doi: 10.24875/AIDSRev.M18000026. Review.

PMID:
30548024
7.

Brief Report: Effectiveness of Trichloroacetic Acid vs. Electrocautery Ablation for the Treatment of Anal High-Grade Squamous Intraepithelial Lesion in HIV-Infected Patients.

Burgos J, Martin-Castillo M, Landolfi S, Dinares MC, Villar J, Navarro J, Ribera E, Falcó V, Curran A.

J Acquir Immune Defic Syndr. 2018 Dec 15;79(5):612-616. doi: 10.1097/QAI.0000000000001847.

PMID:
30179983
8.

Individual patient data meta-analysis of randomized controlled trials of dual therapy with a boosted PI plus lamivudine for maintenance of virological suppression: GeSIDA study 9717.

Perez-Molina JA, Pulido F, Di Giambenedetto S, Ribera E, Moreno S, Zamora J, Coscia C, Alejos B, Pitch J, Gatell JM, De Luca A, Arribas JR.

J Antimicrob Chemother. 2018 Nov 1;73(11):2927-2935. doi: 10.1093/jac/dky299.

PMID:
30085184
9.

Antiretroviral Therapy in Advanced HIV Disease: Which is the Best Regimen?

Burgos J, Ribera E, Falcó V.

AIDS Rev. 2018 Jan-Mar;20(1):3-13. Review.

PMID:
29369304
10.

Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients.

Moltó J, Curran A, Miranda C, Challenger E, Santos JR, Ribera E, Khoo S, Valle M, Clotet B.

J Antimicrob Chemother. 2018 Mar 1;73(3):732-737. doi: 10.1093/jac/dkx459.

PMID:
29237008
11.

Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial.

Pulido F, Ribera E, Lagarde M, Pérez-Valero I, Palacios R, Iribarren JA, Payeras A, Domingo P, Sanz J, Cervero M, Curran A, Rodríguez-Gómez FJ, Téllez MJ, Ryan P, Barrufet P, Knobel H, Rivero A, Alejos B, Yllescas M, Arribas JR; DUAL-GESIDA-8014-RIS-EST45 Study Group.

Clin Infect Dis. 2017 Nov 29;65(12):2112-2118. doi: 10.1093/cid/cix734.

PMID:
29020293
12.

Cardiac surgery in adults with high-surgical complexity CHD: results of a network collaborative programme.

Gilad V, Santoro F, Ribera E, Calevo MG, Cipriani A, Pasquè A, Chierchia SL.

Cardiol Young. 2018 Jan;28(1):101-107. doi: 10.1017/S1047951117001664. Epub 2017 Aug 29.

PMID:
28847320
13.

The role of oncogenic human papillomavirus determination for diagnosis of high-grade anal intraepithelial neoplasia in HIV-infected MSM.

Burgos J, Hernández-Losa J, Landolfi S, Guelar A, Dinares M, Villar J, Navarro J, Ribera E, Falcó V, Curran A.

AIDS. 2017 Oct 23;31(16):2227-2233. doi: 10.1097/QAD.0000000000001605.

PMID:
28723712
14.

A Novel Single-Cell FISH-Flow Assay Identifies Effector Memory CD4+ T cells as a Major Niche for HIV-1 Transcription in HIV-Infected Patients.

Grau-Expósito J, Serra-Peinado C, Miguel L, Navarro J, Curran A, Burgos J, Ocaña I, Ribera E, Torrella A, Planas B, Badía R, Castellví J, Falcó V, Crespo M, Buzon MJ.

MBio. 2017 Jul 11;8(4). pii: e00876-17. doi: 10.1128/mBio.00876-17.

15.

Epidemiological trends of HIV-1 infection in blood donors from Catalonia, Spain (2005-2014).

Bes M, Piron M, Casamitjana N, Gregori J, Esteban JI, Ribera E, Quer J, Puig L, Sauleda S.

Transfusion. 2017 Sep;57(9):2164-2173. doi: 10.1111/trf.14195. Epub 2017 Jul 5.

PMID:
28681400
16.

Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.

Troya J, Ryan P, Ribera E, Podzamczer D, Hontañón V, Terrón JA, Boix V, Moreno S, Barrufet P, Castaño M, Carrero A, Galindo MJ, Suárez-Lozano I, Knobel H, Raffo M, Solís J, Yllescas M, Esteban H, González-García J, Berenguer J, Imaz A; GESIDA-8314 Study Group.

PLoS One. 2017 Feb 9;12(2):e0172184. doi: 10.1371/journal.pone.0172184. eCollection 2017.

17.

Economic impact of optimising antiretroviral treatment in human immunodeficiency virus-infected adults with suppressed viral load in Spain, by implementing the grade A-1 evidence recommendations of the 2015 GESIDA/National AIDS Plan.

Ribera E, Martínez-Sesmero JM, Sánchez-Rubio J, Rubio R, Pasquau J, Poveda JL, Pérez-Mitru A, Roldán C, Hernández-Novoa B.

Enferm Infecc Microbiol Clin. 2018 Mar;36(3):157-164. doi: 10.1016/j.eimc.2016.11.015. Epub 2017 Jan 20. English, Spanish.

PMID:
28109551
18.

Atherogenic properties of LDL particles after switching from Truvada or Kivexa plus lopinavir/r to lamivudine plus lopinavir/r: OLE-MET substudy.

Saumoy M, Tiraboschi JM, Ordoñez-Llanos J, Ribera E, Domingo P, Mallolas J, Curto J, Gatell JM, Podzamczer D.

HIV Clin Trials. 2017 Mar;18(2):49-53. doi: 10.1080/15284336.2016.1275425. Epub 2017 Jan 12.

PMID:
28081673
19.

Acute leg ischaemia in an HIV-infected patient receiving antiretroviral treatment.

Navarro J, Curran A, Burgos J, Torrella A, Ocaña I, Falcó V, Crespo M, Ribera E.

Antivir Ther. 2017;22(1):89-90. doi: 10.3851/IMP3075. Epub 2016 Aug 22.

PMID:
27546463
20.

Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.

Troya J, Ryan P, Ribera E, Podzamczer D, Hontañón V, Terrón JA, Boix V, Moreno S, Barrufet P, Castaño M, Carrero A, Galindo MJ, Suárez-Lozano I, Knobel H, Raffo M, Solís J, Yllescas M, Esteban H, González-García J, Berenguer J, Imaz A; GESIDA-8314 Study Group.

PLoS One. 2016 Oct 11;11(10):e0164455. doi: 10.1371/journal.pone.0164455. eCollection 2016. Erratum in: PLoS One. 2017 Feb 9;12 (2):e0172184.

21.

Effectiveness and safety of an abacavir/lamivudine + rilpivirine regimen for the treatment of HIV-1 infection in naive patients.

Curran A, Rojas J, Cabello A, Troya J, Imaz A, Domingo P, Martinez E, Ryan P, Górgolas M, Podzamczer D, Knobel H, Gutiérrez F, Ribera E.

J Antimicrob Chemother. 2016 Dec;71(12):3510-3514. Epub 2016 Sep 2.

PMID:
27591292
22.

Very low level viraemia and risk of virological failure in treated HIV-1-infected patients.

Teira R, Vidal F, Muñoz-Sánchez P, Geijo P, Viciana P, Ribera E, Domingo P, Castaño M, Martínez E, Roca B, Puig T, Estrada V, Deig E, Galindo MJ, de la Fuente B, Lozano F, Montero M, Muñoz-Sanz A, Sanchez T, Terrón A, Romero-Palacios A, Lacalle JR, Garrido M, Suárez-Lozano I; VACH Study Group.

HIV Med. 2017 Mar;18(3):196-203. doi: 10.1111/hiv.12413. Epub 2016 Aug 1.

23.

Short-length ligamentum arteriosum as a cause of congenital narrowing of the left main stem bronchus.

Sacco O, Santoro F, Ribera E, Magnano GM, Rossi GA.

Pediatr Pulmonol. 2016 Dec;51(12):1356-1361. doi: 10.1002/ppul.23460. Epub 2016 Apr 29.

PMID:
27128381
24.

Improvement of BMD after Switching from Lopinavir/R Plus Two Nucleos(T)ide Reverse Transcriptase Inhibitors to Lopinavir/R Plus Lamivudine: OLE-LIP Substudy.

Crespo M, Navarro J, Martinez-Rebollar M, Podzamczer D, Domingo P, Mallolas J, Saumoy M, Mateo GM, Curran A, Gatell J, Ribera E.

HIV Clin Trials. 2016 May;17(3):89-95. doi: 10.1080/15284336.2016.1149929. Epub 2016 Mar 16.

PMID:
27125363
25.

Executive summary: Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015.

Iribarren JA, Rubio R, Aguirrebengoa K, Arribas JR, Baraia-Etxaburu J, Gutiérrez F, Lopez Bernaldo de Quirós JC, Losa JE, Miró JM, Moreno S, Pérez Molina J, Podzamczer D, Pulido F, Riera M, Rivero A, Sanz Moreno J, Amador C, Antela A, Arazo P, Arrizabalaga J, Bachiller P, Barros C, Berenguer J, Caylá J, Domingo P, Estrada V, Knobel H, Locutura J, López Aldeguer J, Llibre JM, Lozano F, Mallolas J, Malmierca E, Miralles C, Miralles P, Muñoz A, Ocampo A, Olalla J, Pérez I, Pérez Elías MJ, Pérez Arellano JL, Portilla J, Ribera E, Rodríguez F, Santín M, Sanz Sanz J, Téllez MJ, Torralba M, Valencia E, Von Wichmann MA; GESIDA/SEIMC Writing Committee.

Enferm Infecc Microbiol Clin. 2016 Oct;34(8):517-23. doi: 10.1016/j.eimc.2016.02.025. Epub 2016 Apr 5. Review.

PMID:
27056581
26.

Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015.

Iribarren JA, Rubio R, Aguirrebengoa K, Arribas JR, Baraia-Etxaburu J, Gutiérrez F, Lopez Bernaldo de Quirós JC, Losa JE, Miró JM, Moreno S, Pérez Molina J, Podzamczer D, Pulido F, Riera M, Rivero A, Sanz Moreno J, Amador C, Antela A, Arazo P, Arrizabalaga J, Bachiller P, Barros C, Berenguer J, Caylá J, Domingo P, Estrada V, Knobel H, Locutura J, López Aldeguer J, Llibre JM, Lozano F, Mallolas J, Malmierca E, Miralles C, Miralles P, Muñoz A, Ocampo A, Olalla J, Pérez I, Pérez Elías MJ, Pérez Arellano JL, Portilla J, Ribera E, Rodríguez F, Santín M, Sanz Sanz J, Téllez MJ, Torralba M, Valencia E, Von Wichmann MA; GESIDA/SEIMC Writing Committee.

Enferm Infecc Microbiol Clin. 2016 Oct;34(8):516.e1-516.e18. doi: 10.1016/j.eimc.2016.02.004. Epub 2016 Mar 11.

PMID:
26976381
27.

Impact of low-level viraemia on virological failure in HIV-1-infected patients with stable antiretroviral treatment.

Navarro J, Caballero E, Curran A, Burgos J, Ocaña I, Falcó V, Torrella A, Pérez M, Ribera E, Crespo M.

Antivir Ther. 2016;21(4):345-52. doi: 10.3851/IMP3023. Epub 2016 Jan 12.

PMID:
26756461
28.

Mortality, Causes of Death and Associated Factors Relate to a Large HIV Population-Based Cohort.

Garriga C, García de Olalla P, Miró JM, Ocaña I, Knobel H, Barberá MJ, Humet V, Domingo P, Gatell JM, Ribera E, Gurguí M, Marco A, Caylà JA; Barcelona HIV/AIDS working group.

PLoS One. 2015 Dec 30;10(12):e0145701. doi: 10.1371/journal.pone.0145701. eCollection 2015.

29.

The effectiveness of electrocautery ablation for the treatment of high-grade anal intraepithelial neoplasia in HIV-infected men who have sex with men.

Burgos J, Curran A, Landolfi S, Navarro J, Tallada N, Guelar A, Crespo M, Ocaña I, Ribera E, Falcó V.

HIV Med. 2016 Aug;17(7):524-31. doi: 10.1111/hiv.12352. Epub 2015 Dec 21.

30.

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe.

Hofstra LM, Sauvageot N, Albert J, Alexiev I, Garcia F, Struck D, Van de Vijver DAMC, Åsjö B, Beshkov D, Coughlan S, Descamps D, Griskevicius A, Hamouda O, Horban A, Van Kasteren M, Kolupajeva T, Kostrikis LG, Liitsola K, Linka M, Mor O, Nielsen C, Otelea D, Paraskevis D, Paredes R, Poljak M, Puchhammer-Stöckl E, Sönnerborg A, Staneková D, Stanojevic M, Van Laethem K, Zazzi M, Zidovec Lepej S, Boucher CAB, Schmit JC, Wensing AMJ; SPREAD Program, Puchhammer-Stockl E, Sarcletti M, Schmied B, Geit M, Balluch G, Vandamme AM, Vercauteren J, Derdelinckx I, Sasse A, Bogaert M, Ceunen H, De Roo A, De Wit S, Echahidi F, Fransen K, Goffard JC, Goubau P, Goudeseune E, Yombi JC, Lacor P, Liesnard C, Moutschen M, Pierard D, Rens R, Schrooten Y, Vaira D, Vandekerckhove LPR, Van den Heuvel A, Van Der Gucht B, Van Ranst M, Van Wijngaerden E, Vandercam B, Vekemans M, Verhofstede C, Clumeck N, Van Laethem K, Beshkov D, Alexiev I, Lepej SZ, Begovac J, Kostrikis L, Demetriades I, Kousiappa I, Demetriou V, Hezka J, Linka M, Maly M, Machala L, Nielsen C, Jørgensen LB, Gerstoft J, Mathiesen L, Pedersen C, Nielsen H, Laursen A, Kvinesdal B, Liitsola K, Ristola M, Suni J, Sutinen J, Descamps D, Assoumou L, Castor G, Grude M, Flandre P, Storto A, Hamouda O, Kücherer C, Berg T, Braun P, Poggensee G, Däumer M, Eberle J, Heiken H, Kaiser R, Knechten H, Korn K, Müller H, Neifer S, Schmidt B, Walter H, Gunsenheimer-Bartmeyer B, Harrer T, Paraskevis D, Hatzakis A, Zavitsanou A, Vassilakis A, Lazanas M, Chini M, Lioni A, Sakka V, Kourkounti S, Paparizos V, Antoniadou A, Papadopoulos A, Poulakou G, Katsarolis I, Protopapas K, Chryssos G, Drimis S, Gargalianos P, Xylomenos G, Lourida G, Psichogiou M, Daikos GL, Sipsas NV, Kontos A, Gamaletsou MN, Koratzanis G, Sambatakou H, Mariolis H, Skoutelis A, Papastamopoulos V, Georgiou O, Panagopoulos P, Maltezos E, Coughlan S, De Gascun C, Byrne C, Duffy M, Bergin C, Reidy D, Farrell G, Lambert J, O'Connor E, Rochford A, Low J, Coakely P, O'Dea S, Hall W, Mor O, Levi I, Chemtob D, Grossman Z, Zazzi M, de Luca A, Balotta C, Riva C, Mussini C, Caramma I, Capetti A, Colombo MC, Rossi C, Prati F, Tramuto F, Vitale F, Ciccozzi M, Angarano G, Rezza G, Kolupajeva T, Vasins O, Griskevicius A, Lipnickiene V, Schmit JC, Struck D, Sauvageot N, Hemmer R, Arendt V, Michaux C, Staub T, Sequin-Devaux C, Wensing AMJ, Boucher CAB, van de Vijver DAMC, van Kessel A, van Bentum PHM, Brinkman K, Connell BJ, van der Ende ME, Hoepelman IM, van Kasteren M, Kuipers M, Langebeek N, Richter C, Santegoets RMWJ, Schrijnders-Gudde L, Schuurman R, van de Ven BJM, Åsjö B, Kran AB, Ormaasen V, Aavitsland P, Horban A, Stanczak JJ, Stanczak GP, Firlag-Burkacka E, Wiercinska-Drapalo A, Jablonowska E, Maolepsza E, Leszczyszyn-Pynka M, Szata W, Camacho R, Palma C, Borges F, Paixão T, Duque V, Araújo F, Otelea D, Paraschiv S, Tudor AM, Cernat R, Chiriac C, Dumitrescu F, Prisecariu LJ, Stanojevic M, Jevtovic D, Salemovic D, Stanekova D, Habekova M, Chabadová Z, Drobkova T, Bukovinova P, Shunnar A, Truska P, Poljak M, Lunar M, Babic D, Tomazic J, Vidmar L, Vovko T, Karner P, Garcia F, Paredes R, Monge S, Moreno S, Del Amo J, Asensi V, Sirvent JL, de Mendoza C, Delgado R, Gutiérrez F, Berenguer J, Garcia-Bujalance S, Stella N, de Los Santos I, Blanco JR, Dalmau D, Rivero M, Segura F, Elías MJP, Alvarez M, Chueca N, Rodríguez-Martín C, Vidal C, Palomares JC, Viciana I, Viciana P, Cordoba J, Aguilera A, Domingo P, Galindo MJ, Miralles C, Del Pozo MA, Ribera E, Iribarren JA, Ruiz L, de la Torre J, Vidal F, Clotet B, Albert J, Heidarian A, Aperia-Peipke K, Axelsson M, Mild M, Karlsson A, Sönnerborg A, Thalme A, Navér L, Bratt G, Karlsson A, Blaxhult A, Gisslén M, Svennerholm B, Bergbrant I, Björkman P, Säll C, Mellgren Å, Lindholm A, Kuylenstierna N, Montelius R, Azimi F, Johansson B, Carlsson M, Johansson E, Ljungberg B, Ekvall H, Strand A, Mäkitalo S, Öberg S, Holmblad P, Höfer M, Holmberg H, Josefson P, Ryding U.

Clin Infect Dis. 2016 Mar 1;62(5):655-663. doi: 10.1093/cid/civ963. Epub 2015 Nov 29.

31.

Epidemiology of infections by HIV, Syphilis, Gonorrhea and Lymphogranuloma Venereum in Barcelona City: a population-based incidence study.

Martí-Pastor M, García de Olalla P, Barberá MJ, Manzardo C, Ocaña I, Knobel H, Gurguí M, Humet V, Vall M, Ribera E, Villar J, Martín G, Sambeat MA, Marco A, Vives A, Alsina M, Miró JM, Caylà JA; HIV Surveillance Group.

BMC Public Health. 2015 Oct 5;15:1015. doi: 10.1186/s12889-015-2344-7.

32.

Emergency percutaneous, bicaval double-lumen, ECMO cannulation in neonates and infants: insights from three consecutive cases.

Moscatelli A, Buratti S, Gregoretti C, Lampugnani E, Salvati P, Marasini M, Ribera E, Fulcheri E, Tuo P.

Int J Artif Organs. 2015 Sep;38(9):517-21. doi: 10.5301/ijao.5000432. Epub 2015 Sep 29.

PMID:
26428509
33.

Darunavir and ritonavir total and unbound plasmatic concentrations in HIV-HCV-coinfected patients with hepatic cirrhosis compared to those in HIV-monoinfected patients.

Curran A, Martí R, López RM, Pérez M, Crespo M, Melià MJ, Navarro J, Burgos J, Falcó V, Ocaña I, Ribera E.

Antimicrob Agents Chemother. 2015 Nov;59(11):6782-90. doi: 10.1128/AAC.01099-15. Epub 2015 Aug 17.

34.

Multilocus microsatellite typing of Leishmania infantum isolates in monitored Leishmania/HIV coinfected patients.

Tomás-Pérez M, Hide M, Riera C, Montoya L, Bañuls AL, Ribera E, Portús M, Fisa R.

Parasit Vectors. 2015 Jul 22;8:386. doi: 10.1186/s13071-015-0989-9.

35.

Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015).

Expert Panel of GESIDA and the National AIDS Plan, Berenguer J, Polo R, Aldeguer JL, Lozano F, Aguirrebengoa K, Arribas JR, Blanco JR, Boix V, Casado JL, Clotet B, Crespo M, Domingo P, Estrada V, García F, Gatell JM, González-García J, Gutiérrez F, Iribarren JA, Knobel H, Llibre JM, Locutura J, López JC, Miró JM, Moreno S, Podzamczer D, Portilla J, Pulido F, Ribera E, Riera M, Rubio R, Santos J, Sanz-Moreno J, Sanz J, Téllez MJ, Tuset M, Rivero A.

Enferm Infecc Microbiol Clin. 2015 Oct;33(8):544-56. doi: 10.1016/j.eimc.2015.03.017. Epub 2015 May 26.

PMID:
26021186
36.

The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial.

Santos JR, Saumoy M, Curran A, Bravo I, Llibre JM, Navarro J, Estany C, Podzamczer D, Ribera E, Negredo E, Clotet B, Paredes R; Tenofovir/emtricitabine inflUence on LIPid metabolism (TULIP) Study Group.

Clin Infect Dis. 2015 Aug 1;61(3):403-8. doi: 10.1093/cid/civ296. Epub 2015 Apr 13.

PMID:
25870325
37.

[Mechanisms of action, pharmacology and interactions of dolutegravir].

Ribera E, Podzamczer D.

Enferm Infecc Microbiol Clin. 2015 Mar;33 Suppl 1:2-8. doi: 10.1016/S0213-005X(15)30002-1. Review. Spanish.

PMID:
25858605
38.

Risk of progression to high-grade anal intraepithelial neoplasia in HIV-infected MSM.

Burgos J, Curran A, Tallada N, Guelar A, Navarro J, Landolfi S, Villar J, Crespo M, Ribera E, Falcó V.

AIDS. 2015 Mar 27;29(6):695-702. doi: 10.1097/QAD.0000000000000603.

PMID:
25849833
39.

Epidemiology and long-term survival in HIV-infected patients with Pneumocystis jirovecii pneumonia in the HAART era: experience in a university hospital and review of the literature.

López-Sánchez C, Falcó V, Burgos J, Navarro J, Martín MT, Curran A, Miguel L, Ocaña I, Ribera E, Crespo M, Almirante B.

Medicine (Baltimore). 2015 Mar;94(12):e681. doi: 10.1097/MD.0000000000000681. Review.

40.

Atherogenic properties of lipoproteins in HIV patients starting atazanavir/ritonavir or darunavir/ritonavir: a substudy of the ATADAR randomized study.

Saumoy M, Ordóñez-Llanos J, Martínez E, Ferrer E, Domingo P, Ribera E, Negredo E, Curto J, Sánchez-Quesada JL, Di Yacovo S, González-Cordón A, Podzamczer D.

J Antimicrob Chemother. 2015 Apr;70(4):1130-8. doi: 10.1093/jac/dku501. Epub 2014 Dec 23.

PMID:
25538166
41.

Switching from zidovudine/lamivudine to tenofovir/emtricitabine improves fat distribution as measured by fat mass ratio.

Martínez E, Ribera E, Clotet B, Estrada V, Sanz J, Berenguer J, Rubio R, Pulido F, Larrousse M, Curran A, Negredo E, Arterburn S, Ferrer P, Álvarez ML.

HIV Med. 2015 Jul;16(6):370-4. doi: 10.1111/hiv.12210. Epub 2014 Dec 11.

42.

Randomized, crossover, double-blind, placebo-controlled trial to assess the lipid lowering effect of co-formulated TDF/FTC.

Santos JR, Saumoy M, Curran A, Bravo I, Navarro J, Estany C, Podzamczer D, Ribera E, Negredo E, Clotet B, Paredes R.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19550. doi: 10.7448/IAS.17.4.19550. eCollection 2014.

43.

Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: a randomized clinical trial.

Martinez E, Gonzalez-Cordon A, Ferrer E, Domingo P, Negredo E, Gutierrez F, Portilla J, Curran A, Podzamczer D, Ribera E, Murillas J, Bernardino JI, Santos I, Carton JA, Peraire J, Pich J, Deulofeu R, Perez I, Gatell JM; ATADAR Study Group.

Clin Infect Dis. 2015 Mar 1;60(5):811-20. doi: 10.1093/cid/ciu898. Epub 2014 Nov 10.

44.

Liver stiffness and aspartate aminotransferase levels predict the risk for liver fibrosis progression in hepatitis C virus/HIV-coinfected patients.

Gonzalez FA, Van den Eynde E, Perez-Hoyos S, Navarro J, Curran A, Burgos J, Falcó V, Ocaña I, Ribera E, Crespo M.

HIV Med. 2015 Apr;16(4):211-8. doi: 10.1111/hiv.12197. Epub 2014 Sep 18.

45.

Impact of an adherence program to antiretroviral treatment on virologic response in a cohort of multitreated and poorly adherent HIV-infected patients in Spain.

Navarro J, Pérez M, Curran A, Burgos J, Feijoo M, Torrella A, Caballero E, Ocaña I, Ribera E, Crespo M, Falcó V.

AIDS Patient Care STDS. 2014 Oct;28(10):537-42. doi: 10.1089/apc.2014.0097. Epub 2014 Aug 11.

PMID:
25111167
46.

Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014).

Expert Panel of GeSIDA and the National Aids Plan, Berenguer J, Polo R, Lozano F, López Aldeguer J, Antela A, Arribas JR, Asensi V, Blanco JR, Clotet B, Domingo P, Galindo MJ, Gatell JM, González-García J, Iribarren JA, Locutura J, López JC, Mallolas J, Martínez E, Miralles C, Miró JM, Moreno S, Palacios R, Pérez Elías MJ, Pineda JA, Podzamczer D, Portilla J, Pulido F, Ribera E, Riera M, Rubio R, Santos J, Sanz J, Tuset M, Vidal F, Rivero A.

Enferm Infecc Microbiol Clin. 2014 Aug-Sep;32(7):447-58. doi: 10.1016/j.eimc.2014.02.018. Epub 2014 Jun 28.

PMID:
24986715
47.

Darunavir and telaprevir drug interaction: total and unbound plasma concentrations in HIV/HCV-coinfected patients with cirrhosis.

Curran A, Guiu JM, Ribera E, Crespo M.

J Antimicrob Chemother. 2014 May;69(5):1434-6. doi: 10.1093/jac/dkt509. Epub 2013 Dec 19. No abstract available.

PMID:
24363317
48.

[Data on rilpivirine in treatment-naïve patients. Lessons from ECHO, THRIVE and STaR].

Domingo P, Ribera E.

Enferm Infecc Microbiol Clin. 2013 Jun;31 Suppl 2:20-9. doi: 10.1016/S0213-005X(13)70139-3. Review. Spanish.

PMID:
24252530
49.

Ultrasensitive real-time PCR for the clinical management of visceral leishmaniasis in HIV-Infected patients.

Molina I, Fisa R, Riera C, Falcó V, Elizalde A, Salvador F, Crespo M, Curran A, López-Chejade P, Tebar S, Pérez-Hoyos S, Ribera E, Pahissa A.

Am J Trop Med Hyg. 2013 Jul;89(1):105-10. doi: 10.4269/ajtmh.12-0527. Epub 2013 Apr 29.

50.

Tropical diseases screening in immigrant patients with human immunodeficiency virus infection in Spain.

Salvador F, Molina I, Sulleiro E, Burgos J, Curran A, Van den Eynde E, Villar del Saz S, Navarro J, Crespo M, Ocaña I, Ribera E, Falcó V, Pahissa A.

Am J Trop Med Hyg. 2013 Jun;88(6):1196-202. doi: 10.4269/ajtmh.12-0714. Epub 2013 Mar 18.

Supplemental Content

Loading ...
Support Center